FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1925707148> ?p ?o ?g. }

• W1925707148 endingPage "222" @default.
• W1925707148 startingPage "222" @default.
• W1925707148 abstract "To determine the prognostic factors and outcome of first-line induction failure Hodgkin's disease patients who were treated with a salvage regimen of high-dose chemotherapy and autologous stem-cell transplantation, and to compare them with matched, conventionally treated patients.We retrospectively analyzed data relating to 86 Hodgkin's disease patients who underwent autologous stem-cell transplantation after failure of the first chemotherapy regimen, either because they did not enter a complete remission and experienced progression of disease less than 3 months after the end of their first-line treatment or because they showed evidence of disease progression during first-line therapy. Graft patients were matched with 258 conventionally treated patients (three controls per case) for age, sex, clinical stage, B symptoms, and time at risk; patient data were obtained from international databases.Among the 86 graft patients, the median age at diagnosis was 29 years (range, 14 to 57 years). Thirty-nine percent of patients had stage II disease, 23% had stage III disease, and 38% had stage IV disease. Seventy percent of the patients received chemotherapy and 30% received combined modality therapy; 60% of the patients received a seven- or eight-drug regimen. After this first-line treatment, 91% had disease progression and 9% had a brief partial response. Eighty patients received a second-line treatment; pretransplantation status was as follows: 24% of patients had a complete remission, 38% had a partial remission (PR), 14% had stable disease, and disease progression occurred in 24%. With a median follow-up of 22 months (range, 4 to 105 months) from diagnosis, the 5-year event-free survival and overall survival rates from transplantation were 25% and 35% (95% confidence intervals, 15 to 36 and 23 to 49), respectively. In multivariate analysis, the pretransplantation disease status after salvage therapy was the only significant prognostic factor for survival (PR: relative risk = 2.8, P = .017; progressive disease: relative risk (RR) = 5.26, P < .001). From diagnosis, the 6-year overall survival rates of the graft patients and 258 matched conventionally treated patients were 38% and 29%, respectively (P = .058).Autologous stem-cell transplantation represents the best therapeutic option currently available for patients with primary induction failure and is associated with acceptable toxicity. Response to second-line treatment before high-dose chemotherapy is the only prognostic factor that can be correlated with survival." @default.
• W1925707148 created "2016-06-24" @default.
• W1925707148 creator A5002553434 @default.
• W1925707148 creator A5002873056 @default.
• W1925707148 creator A5003078312 @default.
• W1925707148 creator A5007764355 @default.
• W1925707148 creator A5022161221 @default.
• W1925707148 creator A5025226777 @default.
• W1925707148 creator A5025996929 @default.
• W1925707148 creator A5034473496 @default.
• W1925707148 creator A5035275251 @default.
• W1925707148 creator A5036017485 @default.
• W1925707148 creator A5046436694 @default.
• W1925707148 creator A5056514957 @default.
• W1925707148 creator A5063900927 @default.
• W1925707148 creator A5064102980 @default.
• W1925707148 creator A5077504536 @default.
• W1925707148 creator A5078296677 @default.
• W1925707148 creator A5086620890 @default.
• W1925707148 date "1999-01-01" @default.
• W1925707148 modified "2023-10-09" @default.
• W1925707148 title "Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study" @default.
• W1925707148 cites W1511417912 @default.
• W1925707148 cites W1541287496 @default.
• W1925707148 cites W166453000 @default.
• W1925707148 cites W18139128 @default.
• W1925707148 cites W1856398768 @default.
• W1925707148 cites W1895502358 @default.
• W1925707148 cites W1944058895 @default.
• W1925707148 cites W2024892158 @default.
• W1925707148 cites W2071060238 @default.
• W1925707148 cites W2075898541 @default.
• W1925707148 cites W2141082026 @default.
• W1925707148 cites W2158380419 @default.
• W1925707148 cites W2165308914 @default.
• W1925707148 cites W2243629813 @default.
• W1925707148 cites W2255041800 @default.
• W1925707148 cites W2286687528 @default.
• W1925707148 cites W3147894994 @default.
• W1925707148 cites W4293241248 @default.
• W1925707148 doi "https://doi.org/10.1200/jco.1999.17.1.222" @default.
• W1925707148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10458237" @default.
• W1925707148 hasPublicationYear "1999" @default.
• W1925707148 type Work @default.
• W1925707148 sameAs 1925707148 @default.
• W1925707148 citedByCount "148" @default.
• W1925707148 countsByYear W19257071482012 @default.
• W1925707148 countsByYear W19257071482013 @default.
• W1925707148 countsByYear W19257071482014 @default.
• W1925707148 countsByYear W19257071482015 @default.
• W1925707148 countsByYear W19257071482016 @default.
• W1925707148 countsByYear W19257071482017 @default.
• W1925707148 countsByYear W19257071482018 @default.
• W1925707148 countsByYear W19257071482019 @default.
• W1925707148 countsByYear W19257071482020 @default.
• W1925707148 countsByYear W19257071482021 @default.
• W1925707148 countsByYear W19257071482022 @default.
• W1925707148 countsByYear W19257071482023 @default.
• W1925707148 crossrefType "journal-article" @default.
• W1925707148 hasAuthorship W1925707148A5002553434 @default.
• W1925707148 hasAuthorship W1925707148A5002873056 @default.
• W1925707148 hasAuthorship W1925707148A5003078312 @default.
• W1925707148 hasAuthorship W1925707148A5007764355 @default.
• W1925707148 hasAuthorship W1925707148A5022161221 @default.
• W1925707148 hasAuthorship W1925707148A5025226777 @default.
• W1925707148 hasAuthorship W1925707148A5025996929 @default.
• W1925707148 hasAuthorship W1925707148A5034473496 @default.
• W1925707148 hasAuthorship W1925707148A5035275251 @default.
• W1925707148 hasAuthorship W1925707148A5036017485 @default.
• W1925707148 hasAuthorship W1925707148A5046436694 @default.
• W1925707148 hasAuthorship W1925707148A5056514957 @default.
• W1925707148 hasAuthorship W1925707148A5063900927 @default.
• W1925707148 hasAuthorship W1925707148A5064102980 @default.
• W1925707148 hasAuthorship W1925707148A5077504536 @default.
• W1925707148 hasAuthorship W1925707148A5078296677 @default.
• W1925707148 hasAuthorship W1925707148A5086620890 @default.
• W1925707148 hasConcept C126322002 @default.
• W1925707148 hasConcept C141071460 @default.
• W1925707148 hasConcept C146357865 @default.
• W1925707148 hasConcept C151730666 @default.
• W1925707148 hasConcept C2776694085 @default.
• W1925707148 hasConcept C2779050716 @default.
• W1925707148 hasConcept C2779134260 @default.
• W1925707148 hasConcept C2780775027 @default.
• W1925707148 hasConcept C2781413609 @default.
• W1925707148 hasConcept C2911091166 @default.
• W1925707148 hasConcept C71924100 @default.
• W1925707148 hasConcept C86803240 @default.
• W1925707148 hasConceptScore W1925707148C126322002 @default.
• W1925707148 hasConceptScore W1925707148C141071460 @default.
• W1925707148 hasConceptScore W1925707148C146357865 @default.
• W1925707148 hasConceptScore W1925707148C151730666 @default.
• W1925707148 hasConceptScore W1925707148C2776694085 @default.
• W1925707148 hasConceptScore W1925707148C2779050716 @default.
• W1925707148 hasConceptScore W1925707148C2779134260 @default.
• W1925707148 hasConceptScore W1925707148C2780775027 @default.
• W1925707148 hasConceptScore W1925707148C2781413609 @default.
• W1925707148 hasConceptScore W1925707148C2911091166 @default.

• next